ArticleThe American journal of pathology2007
Differential ErbB1 signaling in squamous cell versus basal cell carcinoma of the skin.
Article in The American journal of pathology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 71 citations in OpenAlex.
- Imaging transcriptomics in basal cell carcinoma: Coupling in vivo tumor morphology with gene expression.JID innovations : skin science from molecules to population health · 2026Article
- Lapatinib ameliorates skin fibrosis by inhibiting TGF-β1/Smad and non-Smad signaling pathway.Scientific reports · 2025Article
- Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma.iScience · 2023Review
- Digital Image Analysis-Based Evaluation of Claudin-1 and Claudin-7 Delocalization in Cutaneous Squamous Cell Carcinoma and in Its Precancerous State.Journal of oncology · 2022Article
- The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.Molecular oncology · 2021Article
- Exploring Mycosporine-Like Amino Acids (MAAs) as Safe and Natural Protective Agents against UV-Induced Skin Damage.Antioxidants (Basel, Switzerland) · 2021Review
- The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis.Molecular oncology · 2019Article
- Regulation and Role of GLI1 in Cutaneous Squamous Cell Carcinoma Pathogenesis.Frontiers in genetics · 2019Article
- Restoration of the basement membrane after wounding: a hallmark of young human skin altered with aging.Journal of cell communication and signaling · 2018Article
- Article
- Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase.Oncotarget · 2016Article
- Membrane-Tethered Intracellular Domain of Amphiregulin Promotes Keratinocyte Proliferation.The Journal of investigative dermatology · 2016Article
- iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function.Human molecular genetics · 2014Article
- Molecular profiling of cutaneous squamous cell carcinomas and actinic keratoses from organ transplant recipients.BMC cancer · 2013Article
- Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma.Cancer science · 2012Article
- Heparin-binding EGF-like growth factor promotes epithelial-mesenchymal transition in human keratinocytes.The Journal of investigative dermatology · 2012Article
- Capturing the finer points of gene expression in psoriasis: beaming in on the CCL19/CCR7 axis.The Journal of investigative dermatology · 2012Article
- Patched knockout mouse models of Basal cell carcinoma.Journal of skin cancer · 2012Article
- Activation of the PI3K/AKT pathway in Merkel cell carcinoma.PloS one · 2012Article
- Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma.Journal of experimental & clinical cancer research : CR · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
In this study, we examined ErbB1 signaling in human basal and squamous cell carcinomas (BCC and SCC) of the skin in vivo. We used enzyme-linked immunosorbent assay, laser capture microdissection-coupled real-time reverse transcriptase-polymerase chain reaction, and immunohistochemistry to assess expression and activation levels of ErbB1 protein, ligands, and potential downstream effectors, in BCC and SCC tumors, stroma, and adjacent epidermis. Although total ErbB1 protein and mRNA were similar in cancerous and normal skin, we found that ErbB1 activation (phospho-Tyr(1068)) was greater in bulk SCC versus BCC or normal skin. In addition, three ErbB1 ligand transcripts (amphiregulin, heparin-binding epidermal growth factor-like growth factor, and transforming growth factor-alpha) were up-regulated in tumor cells of SCC but not BCC. Expression of these ligands was also increased in asymptomatic epidermis adjacent to both SCC and BCC, relative to normal skin. Interestingly, betacellulin transcript levels were inversely regulated compared with the other ligands. Consistently, downstream ErbB1 effectors (Erk1/2 and Akt) were activated in tumor cells of SCC but not of BCC and in adjacent epidermis of both BCC and SCC. These results demonstrate that ErbB1 signaling is hyperactive in tumor cells of SCC but not of BCC and in nearby asymptomatic epidermis of both tumor types. Our results suggest that targeting ErbB1 signaling might be of benefit in the treatment of SCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.